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Abstract 
Plasminogen activator inhibitor-1 is known to play a paradoxical positive role in tumor 
angiogenesis, but its contribution to metastatic spread remains unclear. We studied the impact 
of PAI-1 deficiency in a transgenic mouse model of ocular tumors originating from retinal 
epithelial cells and leading to brain metastasis (TRP-1/SV40 Tag mice). PAI-1 deficiency did 
not affect primary tumor growth or vascularization, but was associated with a smaller number 
of brain metastases. Brain metastases were found to be differentially distributed between the 
two genotypes. PAI-1-deficient mice displayed mostly secondary foci expanding from local 
optic nerve infiltration, whereas wild-type animals displayed more disseminated nodules in 
the scissura and meningeal spaces. SuperArray GEArray analyses aiming to detect molecules 
potentially compensating for PAI-1 deficiency demonstrated an increase in fibroblast growth 
factor-1 (FGF-1) gene expression in primary tumors, which was confirmed by RT-PCR and 
western blotting. Our data provide the first evidence of a key role for PAI-1 in a spontaneous 
model of metastasis, and suggest that angiogenic factors, such as FGF-1, may be important 
for primary tumor growth and may compensate for the absence of PAI-1. They identify PAI-1 
and FGF-1 as important targets for combined anti-tumor strategies. 
 
Introduction 
Angiogenesis — the formation of new blood vessels — is an important rate-limiting step 
during tumor growth and metastatic dissemination. This process requires the coordinated 
regulation of adhesive, proteolytic and migrating events involving different proteolytic 
systems. Many clinical studies have established a correlation between adverse outcome in 
patients with multiple cancer types and high levels of serine proteases of the plasminogen 
activator (PA) system (for review, see Andreasen et al., 1997). The urokinase-type (uPA) and 
tissue-type (tPA) plasminogen activators (Rakic et al., 2003). Both uPA and tPA are inhibited 
by several serine protease inhibitors (SERPINs) including plasminogen activator inhibitor-1 
(PAI-1), PAI-2, PAI-3 (protein C inactivator), protease nexin-1 (PN-1) and mammary serine 
protease inhibitor (Maspin) (Potempa et al., 1994; Rakic et al., 2003). In addition to its 
inhibitory role during PA-mediated proteolysis, PAI-1 also interacts with vitronectin involved 
in cell adhesion and migration (Stefansson and Lawrence, 1996; Deng et al., 2001), and LRP 
(low-density lipoprotein receptor-related protein implicated in the endocytosis of cell surface 
molecules (Czekay and Loskutoff, 2004; Balsara et al., 2006). 
As an inhibitor of uPA, PAI-1 was long thought to be an inhibitor of tumorigenesis and 
angiogenesis. However, a number of clinical studies reported a correlation between PAI-1 
overexpression in human tumors and a poor prognosis (Andreasen et al., 1997; Duffy, 2004). 
A dose-dependent effect of PAI-1 on pathological angiogenesis has been observed both in 
vitro (Devy et al., 2002) and in vivo (Lambert et al., 2003; McMahon et al., 2001; Stefansson 
et al., 2001; Bajou et al., 2004). Tumor growth and angiogenesis are impaired in mice with a 
PAI-1 gene deletion (Bajou et al., 1998; Gutierrez et al., 2000; Maillard et al., 2005) or 
following the induction of PAI-1 expression at supraphysiological levels by adenoviral gene 
transfer or tumor cell transfection, the administration of recombinant PAI-1 protein and in 
transgenic mice overexpressing PAI-1 (Soff et al., 1995; Praus et al., 1999; Ma et al., 1997; 
McMahon et al., 2001; Bajou et al., 2004). 
The impact of PAI-1 on metastatic dissemination is less clear. An increase in pulmonary 
metastasis has often been observed in response to PAI-1 administration (Tsuchiya et al., 
1997). However, other studies have reported no difference in metastatic dissemination with 
PAI-1 level (Eitzman et al., 1996). These data obtained after induction of experimental 
tumors by massive tumor cell injection may not be representative of events in the 
pathogenesis of real cancers. Genetically engineered mouse models that spontaneously 
develop cancer in a target organ may thus provide a powerful tool for more accurately 
mimicking the natural history of cancer. A single study has evaluated the impact of PAI-1 
deficiency in a transgenic mouse model of cancer (Almholt et al., 2003). Primary breast 
tumor development and lung metastasis were similar in MMTV-PymT mice with and without 
PAI-1 expression (Almholt et al., 2003). It remains unclear whether possible compensatory or 
redundant mechanisms can mediate tumor angiogenesis and metastatic dissemination in the 
absence of PAI-1. We backcrossed PAI-1-deficient mice with TRP-1/SV40 Tag transgenic 
mice, which spontaneously develop ocular tumors derived from retinal pigmented epithelium 
(RPE), leading to brain metastasis (Penna et al., 1998). We provide evidence that PAI-1 
deficiency has no effect on primary ocular tumor growth, but reduces brain metastasis. This 
report provides the first demonstration that PAI-1 contributes to the early steps of metastatic 
dissemination in a transgenic mouse tumor model recapitulating all the steps of metastasis. 
Attempts to identify molecules potentially compensating for PAI-1 deficiency demonstrated 
increase in levels of mRNA and protein for fibroblast growth factor-1 (FGF-1) in primary 
tumors. 
 
Materials and methods 
 
Genetically modified mice 
 
TRP-1/SV40 Tag transgenic mice were generated by insertion into Y chromosome of a 
1.4 kb fragment of tyrosine-related protein 1 (TRP-1) promoter fused to SV40 Tag 
transforming sequence (Penna et al., 1998). Female PAI-1-deficient mice (PAI-1-/-) (Bajou et 
al., 1998) were mated with male TRP-1/SV40 Tag transgenic mice. F1 males heterozygous 
for both genes were backcrossed either with PAI-1-/- females or with the corresponding wild-
type control (WT). All animals used were maintained under specific pathogen-free conditions, 
with a 12 h light/12 h dark cycle and free access to food and water. 
 
Tissue sample collection and brain metastasis analysis 
 
For histological analysis, animals were killed 64 days after birth. The entire head of each 
animal was fixed in 4% formalin. After overnight decalcification (Sakura Finetek, 
Zoeterwoude, The Netherlands), tissue samples were rinsed in water for 1 h and incubated in 
4% formalin for 1 h. Five frontal fragments of the head were cut to isolate several brain areas 
covering the entire organ. Paraffin sections cut from each head fragment (5 per animal) were 
stained with hematoxylin and eosin. Total number of metastases per mouse was determined as 
the number of metastatic foci on 5 sections for each animal (n=22 for PAI-1-/- and n=19 for 
WT mice). Incidence of metastasis was calculated as the percentage of mice with one or more 
metastatic nodules in the brain. Metastasis severity was scored as: minimal (score 0 = no 
metastatic nodule), medium (score 1 = less than 4 metastatic nodules), or extensive 
involvement (score 2 = 5 to 7 metastatic nodules). 
Gene array 
 
Total RNA was extracted from the eyes of 10 TRP-1/PAI-1-/- and 9 control TRP-1/PAI-
1+/+ mice (2 month-old), using High Pure RNA isolation kit (Roche Diagnostics, Mannheim, 
Germany). Relative mRNA expression levels were determined for genes involved in tumor 
progression and cancer metastasis, using the GEarray (SuperArray Inc., Frederick, MD), 
according to manufacturer’s protocol. Array images were digitized by densitometric scanning 
on a Fluor-S MultiImager (Bio-Rad Laboratories, Hercules, CA) and analysed by using 
GEArray Expression Analysis Suite software (SuperArray). Values were normalized with 
respect to the signal for a housekeeping gene (GAPDH). Genes were considered to be 
differentially expressed if the ratio between control and PAI-1-/- mice was greater than 1.5. 
 
Reverse Transcriptase-PCR analysis 
 
RT-PCR amplification was carried out with the GeneAmp Thermostable rTth reverse 
transcriptase RNA PCR kit (Perkin Elmer Life Sciences, Boston, MA) with specific pairs of 
primers (Table I). RT-PCR products were resolved by electrophoresis in 10% polyacrylamide 
gels and analyzed with a Fluor-S MultiImager after staining with Gelstar dye (FMC 
BioProducts, Heidelberg, Germany). RT-PCR products were quantified by normalization with 
respect to 28S rRNA. 
 
Western blotting  
 
Entire eyes collected on day 64 were placed in lysis tubes (MagNA Lyser Green Beads, 
Roche Diagnostics) containing 300 µl of lysis buffer (50 mM Tris/HCl, pH 7.5; 110 mM 
NaCl; 10 mM EDTA; 5 mM iodoacetamide; 0.1% NP40). Protein extracts were collected by 
centrifugation at 12,000 rpm, at 4°C for 30 minutes. Protein concentration was determined 
with DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). Samples (30 µg of protein) 
were resolved by SDS-PAGE in 15% polyacrylamide gels under reducing conditions and 
proteins were transferred to PVDF membranes (NEN, Boston, MA). Membranes were 
incubated for 2 h in blocking TBS buffer (25 mM Tris/HCl, pH7.6; 150 mM NaCl, 0.1% 
Tween 20) supplemented with 5% nonfat milk powder. They were then incubated overnight 
with a polyclonal goat antibody directed against human FGF-1 (R&D systems, Minneapolis). 
Membranes were washed and incubated for 1h with secondary horseradish peroxidase-
conjugated rabbit anti-goat antibody (DAKO, Glostrup, Denmark). Signals were detected 
with an enhanced chemiluminescence (ECL) kit (Perkin Elmer Life Sciences, Boston) 
according to manufacturer’s instructions. GAPDH detection was carried out (using a rabbit 




Statistical differences between experimental groups were assessed with Mann-Whitney 
test. Chi-squared analysis was used to compare metastasis incidence between groups. Log 
rank tests were used to compare survival curves. Prism 4.0 software (GraphPad, San Diego, 
CA) was used and P-values < 0.05 were considered significant. 
Results  
 
PAI-1 gene deficiency does not prevent the development of primary ocular tumors 
 
Primary ocular tumor development was monitored at day 64 after birth in a cohort of 
TRP-1 PAI-1-/- (n=22) and TRP-1 PAI-1+/+ (WT, n=19) mice (Figure 1A,B). In mice of both 
genotypes, the entire eyeball and optic nerves were filled by cuboidal neoplastic cells 
arranged in a tubular fashion, similar to that observed in human carcinomas of the retinal 
pigmentory epithelium (RPE) (Penna et al., 1998). No difference in tumor histology or 
vascularization was observed between the two experimental groups (data not shown). 
 
The development of brain metastases is delayed in PAI-1 knockout mice  
 
Brain metastases developed in 100 % of two-month old TRP-1 transgenic mice. They 
were quantified by cutting the head of each mouse (n = 22 for PAI-1-/- and n=19 for WT 
mice) frontally into five distinct fragments. Sections (5 µm) were prepared from each 
fragment and metastasis nodules were counted on each slide (5 per animal). Since brain 
metastases occurred preferentially at three sites, the distribution of metastases (disseminated 
foci versus local foci expanding from optic nerve invasion) was also analyzed (Figure 2). 
For all secondary nodules detected in the brain, both the incidence (percentage of animals 
with metastases) and severity (number of metastatic nodules per animal) of metastases were 
affected by PAI-1 deficiency. PAI-1-deficient mice had fewer secondary lesions than 
corresponding WT mice. The mean number of metastases per animal was 2.5 +/- 0.3 nodules 
in PAI-1-/- versus 3.7 +/- 0.5 nodules in WT mice (p=0.02) (Figure 3A). In the absence of 
PAI-1, 14 % of mice did not display metastasis (severity 0), whereas 100% of WT animals 
showed brain metastases (Figure 4). Severity 2 (more than 5 nodules per mouse) metastasis 
was observed in 37% of WT animals, but in none of the PAI-1-/- transgenic mice (Figure 4) 
(p<0.01).  
The main localization of secondary foci was brain parenchyma basis where optic nerves 
infiltrated by tumor cells come into close contact with brain parenchyma (I in Figure 2A and 
2B). These nodules correspond to local invasion through optic nerve infiltration rather than to 
distant metastases. Metastatic nodules were found in scissura or meningeal spaces (II in 
Figure 2A and 2C) and in the anterior part of the brain, between the two olfactory lobes (III in 
Figure 2A and 2D). These three topographic distributions were frequently found in control 
mice. In sharp contrast, most of the secondary foci in PAI-1-deficient animals expanded from 
the brain base through optic nerve infiltration, with other distant nodules found only rarely. 
Indeed, WT mice developed significantly more disseminated brain nodules than did PAI-1 
knockout animals (1.7 +/- 0.3 nodules in WT versus 1 +/- 0.2 nodules in PAI-1-/- mice, 
p=0.03) (Figure 3B and C). 
Metastatic brain invasion led to animal death. Transgenic PAI-1-/- mice had fewer brain 
metastases, but survival was not affected by PAI-1 status. The median survival was 95 days 
for PAI-1-/- mice and 92.5 days for WT mice (data not shown). 
 
Expression patterns of several factors during tumor follow-up 
  
As PAI-1 deficiency delayed the development of brain metastasis but did not influence 
primary tumor progression in the TRP-1/SV40 Tag line, we hypothesized that other 
components of related proteolytic systems might compensate for the absence of PAI-1. The 
expression of genes encoding several protease-related candidates was evaluated by semi-
quantitative RT-PCR analysis on primary ocular tumors. The molecules studied included 
components of the plasminogen/plasmin system (tPA, uPA, uPAR, PAI-1, PAI-2, PN-1 and 
MASPIN), several members of metalloproteinase family putatively involved in angiogenesis 
(MMP-2, MMP-9, MMP-13 and MMP-14) and their inhibitors (TIMP-1, TIMP-2, TIMP-3 
and RECK), and the most important known angiogenic factor, VEGF-A. PAI-1 expression 
levels were used as an internal control. All the factors studied displayed similar levels of 
expression in presence and absence of PAI-1, with the exception of TIMP-2 for which larger 
amounts of mRNA were produced in PAI-1-/- mice than in WT mice (0.92 +/- 0.05 arbitrary 
units in knockout mice versus 0.76 +/- 0.02 in WT mice, p=0.005) (Table II). 
We extended this expression profiling, using a GEarray containing 96 cDNA fragments 
printed in quadruplicate (tetra-spots) on a nylon membrane. We identified four genes 
upregulated by a factor of 1.8 to 2.2 in KO mice: FGF-1, Mucin-1, Ncam-1 and TIMP-2 
(Table II). Array verification by semi-quantitative RT-PCR on samples identical to those used 
for array analysis confirmed the upregulation of FGF-1 (p=0.001) and TIMP-2 (p=0.05) 
mRNA levels in PAI-1-deficient animals, but not that of Ncam-1 and Mucin-1 levels (Figure 
5). 
TIMP-2 protein levels were shown, by ELISA, to be similar in TRP-1 PAI-1-deficient 
and -proficient mice (p=0.7, data not shown). In contrast, levels of FGF-1 production, 
assessed by western blotting, were higher in ocular tumors of TRP-1 PAI-1-/- mice than in 
those of their controls (p=0.008, Figure 6).  
Discussion 
 
Evidence is accumulating that PAI-1 is a potent regulator of angiogenesis and tumor 
growth (Rakic et al., 2003; Lee and Huang, 2005). Animal tumor models have contributed to 
characterize PAI-1 functions during tumor development. Nevertheless, conflicting results 
have been obtained, possibly due to the great diversity of experimental models used (tumor 
type, number of tumor cells, implantation site) and dose-dependent PAI-1 effects. Further 
studies in spontaneous carcinogenesis models are required. We investigated the contribution 
of PAI-1 to spontaneous metastasis, using a model of ocular carcinogenesis including all 
stages of cancer progression and metastasis formation. By crossing a PAI-1-null allele into 
TRP-1 mice, we provide the first evidence that PAI-1 contributes to distant metastases in a 
transgenic tumor model and that increases in the production of an angiogenic factor, FGF-1, 
might account for similar primary tumor growth in PAI-1-deficient and -proficient mice.  
Primary tumor growth and vascularization were found to be similar in PAI-1-proficient 
and -deficient mice. However, this does not exclude the possibility that PAI-1 contributes to 
earlier steps in cancer progression. We previously showed, in murine and human skin 
carcinomas (Bajou et al., 1998; Bajou et al., 2001; Maillard et al., 2005), that PAI-1 is a pro-
angiogenic factor and a crucial determinant of tumor microenvironment regulating early 
stages of primary tumor implantation and growth. However, once the tumor has developed, 
PAI-1 is no longer essential for cancer progression (Maillard et al., 2005). Accordingly, PAI-
1 deficiency does not affect primary tumor development in MMTV-PymT model (Almholt et 
al., 2003). The similar development of primary tumors in both genotypes allowed unbiased 
comparison of metastases. We show here that PAI-1 deficiency is associated with smaller 
numbers of brain metastases. We also found that the distribution of metastases was different 
in PAI-1+/+ and PAI-1-/- brains. Secondary foci in PAI-1-/- mice were mostly derived from 
local infiltration of optic nerves, expanding toward brain parenchyma, whereas more distant 
metastatic foci were detected in the scissura and meningeal spaces of WT animals. This 
constitutes the first demonstration that PAI-1 deficiency affects metastatic dissemination in a 
model of spontaneous carcinogenesis. 
A possible explanation for the lack of effect of PAI-1 deficiency on the growth of primary 
TRP-1/SV40 Tag eye tumors is a functional overlap between PAI-1 and other protease 
inhibitors. We therefore searched for functional redundancy, focusing on alternative inhibitors 
of matrix remodeling (PAI-2, PN-1, Maspin, TIMPs) and other compounds of PA and MMP 
proteolytic systems putatively involved in angiogenesis. Such a functional overlap between 
MMP and PA systems has been demonstrated in wound healing (Lund et al., 1999). However, 
our transgenic tumor model provided no evidence that PAI-1 deficiency led to functional 
redundancy or a compensatory increase in the levels of proteases or their inhibitors. By using 
a more global approach based on Superarray GEarray technology, increased FGF-1 
production in primary tumors was detected at mRNA levels and confirmed at protein levels. 
FGF-1 is not only angiogenic, but also acts as an important survival factor for normal RPE 
cells or endothelial cells (Bryckaert et al., 2000; Guillonneau et al., 1997; Uriel et al., 2006). 
FGF-1 therefore probably promotes primary RPE tumor growth and angiogenesis through 
several mechanisms. 
There is an apparent discrepancy between the dramatic effects of PAI-1 deficiency in 
transplanted human and murine tumor models (Bajou et al., 1998; Gutierrez et al., 2000; 
Maillard et al., 2005; Lee and Huang, 2005) and the absence of an impact on spontaneous 
tumor development in carcinogenesis models, such as MMTV-PymT (Almholt et al., 2003) 
and TRP-1/SV40 Tag transgenic mice. One possible reason is that compensatory 
mechanisms, such as angiogenic molecule production, can take place in transgenic mice 
during development and growth, but not in mice challenged by massive tumor cell injections. 
The higher levels of FGF-1 production observed in TRP-1/SV40 Tag tumors was not detected 
in the skin transplantation model used in previous studies (Bajou et al., 1998) (data not 
shown). This suggests that FGF-1 overproduction may be specific to RPE tumors or take 
place throughout pathological angiogenesis, as a host response, and not during transient 
challenge. Carcinogenesis models thus better reflect the real pathogenesis of cancer and may 
provide important information regarding host reaction to the long-term inhibition or deletion 
of a specific gene product. 
PAI-1 is a multifunctional protein. In addition to its serpin function, it also binds to 
vitronectin, thereby regulating cell adhesion and migration (Czekay and Loskutoff, 2004). 
This protein also has a LRP binding site involved in controlling cell migration via uPA/uPAR 
internalization (Herz and Strickland 2001) and in regulating cell proliferation and apoptosis 
via the PI3K/AKT pathway (Balsara et al., 2006). To dissect functional properties of PAI-1, 
we and others have used mutated forms of rPAI-1 that unraveled novel PAI-1 activities 
unrelated to serine protease-inhibitory activity (Bajou et al., 2001; Lambert et al., 2003; Praus 
et al., 2002; Stefansson et al., 2001; Balsara et al., 2006). However, this strategy is hampered 
in the present model, by the occurrence of tumor transformation and progression in utero and 
the impossibility of using adenovirus-mediated gene transfer or recombinant protein injection 
at early stages. In addition, the anatomy of the eye hinders the access of pharmacological 
compounds to intraocular environment in neonatal or adult mice (Bouquet et al., 2003). 
Pharmacological compounds modulating PAI-1 activities are currently under 
development (Leik et al. 2006; Liang et al. 2005). However, particular features of PAI-1 
might raise concerns about its targeting for treatment purposes and should be carefully 
addressed: 1) its multifunctionality, 2) its short half-life in vivo, 3) its dose-dependent effect, 
and finally 4) its impact on the fibrinolytic system and on the process of atherosclerosis and 
thrombosis. A strategy based on the use of specific stabilized mutants interfering with binding 
to vitronectin, but without affecting PA activity, can be used to block angiogenesis without 
affecting fibrinolysis or thrombosis (Stefansson et al., 2001). Despite major progress toward 
the development of pharmacological PAI-1 inhibitors, there is currently no evidence to 
suggest that compensatory mechanisms are induced following the deletion or long-term 
inhibition of PAI-1. Our study provides the first evidence of an increase in FGF-1 production 
in the absence of PAI-1 gene. This may account for the lack of a phenotype in the 
development of primary tumors in PAI-1-deficient mice and may, at least partly, account for 
some of the conflicting data reported in previous studies. Our data highlight the need for 
further investigations before the clinical use of PAI-1-targeting compounds. The recent 
approval of anti-angiogenic agents for clinical applications has not only provided a proof-of-
concept for anti-angiogenic strategies, but has also highlighted the possible progressive 
emergence of resistance to treatment (Carmeliet, 2005). Our data suggest that the long-term 
targeting of PAI-1 might be counteracted by the overproduction of angiogenic factors, such as 
FGF-1. Further studies, in other models, are urgently required to address this important issue. 
Legends to figures 
Figure 1 
Frontal sections (5 µm) of the head crossing the middle of the eyes, from TRP-1 WT (A) and 
TRP-1 PAI-1 knockout (PAI-1-/-) mice (B). Mice were killed 64 days after birth and 
histological sections were stained with hematoxylin and eosin (H&E). E, primary eye tumor; 
ON, optic nerve; B, Brain. Original magnification: 10x. Bars, 2 mm. 
 
Figure 2 
Localization of metastasis in the brain. A: Schematic sagittal section of the head visualizing 
the three preferential sites of metastases (I, II and III). B, C and D: Frontal brain sections 
stained with hematoxylin and eosin. Tumor cells invading optic nerves formed nodules in the 
brain parenchyma adjacent to these nerves (I in panels A and B). Some metastases 
disseminated in the meningeal spaces (II in panels A and C). Nodules were also detected 
between the two olfactory lobes in frontal sections crossing the eyes (III in panels A and D). 
 
Figure 3 
Quantification of brain metastases in TRP-1 PAI-1-/- and TRP-1 control animals. TRP-1 PAI-
1+/+ (WT, ■, n=19) and TRP-1 PAI-1-/- (▲, n=22) mice were killed 64 days after birth. For 
each animal, nodules were counted on five different brain sections stained with H&E, to 
obtain a total number of metastases per animal (A). Disseminated nodules were quantified by 
counting the total number of nodules in the anterior part of the brain (between the 2 olfactory 
lobes) and in meningeal spaces (B) (see the legend to figure 2). Nodules expanding from optic 
nerves correspond to the infiltration of 1 or 2 optic nerves and propagation to close cerebral 
parenchyma (C). Horizontal bars represent median values, P-values correspond to the Mann-
Whitney test (* P≤ 0.05; NS, non significant value). 
Figure 4 
Severity of brain metastases. The severity of metastases was determined as described in 
materials and methods. Severity 0: no detectable metastases; severity 1: 1 to 4 nodules per 




Gene array verification by semi-quantitative RT-PCR analysis. Total RNA was extracted 
from eye tumors of 11 TRP-1 PAI-1-deficient and 9 TRP-1 control mice killed on day 64. 
Levels of 28S rRNA (A) and PAI-1 mRNA (B) were assessed as controls. For each PCR 
product studied (B: PAI-1, C: FGF-1, D: Mucin-1, E: Ncam-1 and F: TIMP-2), the upper 
panel shows a representative polyacrylamide gel with 6 representative samples from WT (left 
part) and PAI-1 KO mice (right part). The expected sizes of amplified products are indicated 
on the right. Scatter plots (below panels) correspond to the densitometric quantification of 
PCR products. Results are expressed as amplified mRNA level divided by 28S ribosomal 
RNA level. Horizontal bars indicate mean values, P-values correspond to Mann-Whitney tests 
(* P≤ 0.05; *** P≤ 0.005; NS, non significant). 
 
Figure 6 
Western blot analysis of FGF-1 production in TRP-1 transgenic mice with and without 
deletion of PAI-1 gene. A: Western-blot analysis of 3 representative samples from WT and 
PAI-1-/- mice. Recombinant human (rh) FGF-1 was used as positive control. GAPDH protein 
levels were assessed as a loading control. B: quantification of FGF-1 production by scanning 
densitometry in WT (white bars) and PAI-1-/- (black bars) mice. Results are expressed as 
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  Forward primer (5’→3’) Reverse primer (5’→3’) Cycles (n) 
MMP-2 5’-AGATCTTCTTCTTCAAGGACCGGTT-3’  5’-GGCTGGTCAGTGGCTTGGGGTA-3’  27 
MMP-9 5’-GCGGAGATTGGGAACCAGCTGTA-3’ 5’-GACGCGCCTGTGTACACCCACA-3’ 35 
MMP-13 5’-ATGATCTTTAAAGACAGATTCTTCTGG-3’  5’-TGGGATAACCTTCCAGAATGTCATAA-3’ 33 
MMP-14 5’- GGATACCCAATGCCCATTGGCCA-3’  5’-CCATTGGGCATCCAGAAGAGAGC-3’  27 
TIMP-1 5’-CATCCTGTTGTTGCTGTGGCTGAT-3’ 5’-GTCATCTTGATCTCATAACGCTGG-3’ 30 
TIMP-2 5’-CTCGCTGGACGTTGGAGGAAAGAA-3’ 5’-AGCCCATCTGGTACCTGTGGTTCA-3’ 25 
TIMP-3 5’-CTTCTGCAACTCCGACATCGTGAT-3’ 5’-CAGCAGGTACTGGTACTTGTTGAC-3’ 27 
RECK 5’- GGCCCTTGCCAGCCTTTCTGCAGA-3’ 5’-ACAGCAAGCCCCTGGTGGGATGA-3’ 33 
uPA 5’-ACTACTACGGCTCTGAAGTCACCA-3’ 5’-GAAGTGTGAGACTCTCGTGTAGAC-3’ 30 
tPA 5’-CTACAGAGCGACCTGCAGAGAT-3’ 5’-AATACAGGGCCTGCTGACACGT-3’ 27 
uPAR 5’-ACTACCGTGCTTCGGGAATG-3’ 5’-ACGGTCTCTGTCAGGCTGATG-3’ 30 
PAI-1 5’-AGGGCTTCATGCCCCACTTCTTCA-3’ 5’-AGTAGAGGGCATTCACCAGCACCA-3’ 30 
PAI-2 5’-CTCAAACCAAAGGTGAAATCCCAA-3’ 5’-GGTATGCTCTCATGCGAGTTCACA-3’ 30 
Maspin 5’-CACAGATGGCCACTTTGAGGACAT-3’ 5’-GGGAGCACAATGAGCATACTCAGA-3’ 27 
PN-1 5’- GGTCCTACCCAAGTTCACAGCTGT-3’ 5’-AGGATTGCAGTTGTTGCTGCCGAA-3’ 27 
VEGF-A 5’-CCTGGTGGACATCTTCCAGGAGTA-3’ 5’-CTCACCGCCTCGGCTTGTCACA-3’ 33 
FGF-1 5’-GGCTGAAGGGGAGATCACAACCTT-3’ 5’-CATTTGGTGTCTGCGAGCCGTATA-3’ 29 
Mucin-1 5’-GTGCTGGTCTGTATTTTGGTTGCT-3’ 5’-GTCACCACAGCTGGGTTGGTATAA-3’ 27 
Ncam-1 5’-GCTATCTGGAGGTGACCCCAGATT-3’ 5’-CCTCCATGTTGGCTTCTTTGGCAT-3’ 27 
28s 5’-GTTCACCCACTAATAGGGAACGTGA-3’ 5’-GATTCTGACTTAGAGGCGTTCAGT-3’ 15 
Table 1. Sequences of primers used for RT-PCR studies. 
  Semi-quantitative RT-PCR Gearray 
 
Plasminogen/plasmin system : 
 
uPA = = 
tPA = = 
uPAR = = 
PAI-1 WT>KO WT>KO 
PAI-2 = = 
PN-1 = Absent from the membrane 
Maspin = = 
MMPs and their inhibitors :  
MMP-2 = = 
MMP-9 = = 
MMP-14 = = 
MMP-13 = = 
TIMP-1 = = 
TIMP-2 KO>WT KO>WT 
TIMP-3 = = 
RECK = Absent from the membrane 
Angiogenic factor : VEGF-A = = 
Other regulated factors :  
FGF-1  KO>WT 
Mucin-1  KO>WT 
Ncam-1  KO>WT 
Table 2. Studies of gene expression by semi-quantitative RT-PCR analysis and Superarray membrane on total RNA extracted from eye 
tumors of TRP-1 PAI-1-/- (KO) and TRP-1 PAI-1 +/+ (WT) mice. =, similar expression level; WT>KO, higher expression level in WT than in 
KO mice; KO>WT, higher expression level in KO than in WT mice. 
